State Board of Administration of Florida Retirement System Has $976,000 Stake in Clovis Oncology Inc (CLVS)

State Board of Administration of Florida Retirement System held its position in Clovis Oncology Inc (NASDAQ:CLVS) during the fourth quarter, Holdings Channel reports. The firm owned 21,979 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. State Board of Administration of Florida Retirement System’s holdings in Clovis Oncology were worth $976,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Consonance Capital Management LP boosted its position in Clovis Oncology by 20.3% in the third quarter. Consonance Capital Management LP now owns 3,531,487 shares of the biopharmaceutical company’s stock worth $127,310,000 after buying an additional 595,000 shares during the period. Rice Hall James & Associates LLC boosted its position in Clovis Oncology by 12.3% in the third quarter. Rice Hall James & Associates LLC now owns 106,207 shares of the biopharmaceutical company’s stock worth $3,829,000 after buying an additional 11,613 shares during the period. Blue Jay Capital Management LLC purchased a new position in Clovis Oncology during the third quarter worth $12,077,000. Tocqueville Asset Management L.P. purchased a new position in Clovis Oncology during the third quarter worth $1,532,000. Finally, Bank of New York Mellon Corp boosted its position in Clovis Oncology by 5.6% in the third quarter. Bank of New York Mellon Corp now owns 174,027 shares of the biopharmaceutical company’s stock worth $6,274,000 after buying an additional 9,292 shares during the period. Institutional investors and hedge funds own 88.48% of the company’s stock.

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology Inc (NASDAQ:CLVS) opened at 70.32 on Friday. The company’s market capitalization is $3.14 billion. The stock has a 50 day moving average of $63.34 and a 200-day moving average of $45.12. Clovis Oncology Inc has a 12-month low of $11.57 and a 12-month high of $74.94.

Clovis Oncology (NASDAQ:CLVS) last announced its quarterly earnings data on Wednesday, February 22nd. The biopharmaceutical company reported ($1.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by $0.18. The business earned $0.08 million during the quarter. During the same period last year, the company posted ($3.12) EPS. Equities analysts expect that Clovis Oncology Inc will post ($5.31) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Web Breaking News and is the sole property of of Web Breaking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at http://www.webbreakingnews.com/2017/03/25/state-board-of-administration-of-florida-retirement-system-has-976000-stake-in-clovis-oncology-inc-clvs.html.

A number of research analysts have weighed in on CLVS shares. Bank of America Corp started coverage on shares of Clovis Oncology in a research report on Friday, January 27th. They set a “buy” rating and a $74.00 price objective on the stock. Vetr upgraded shares of Clovis Oncology from a “sell” rating to a “buy” rating and set a $39.27 price objective on the stock in a research report on Monday, November 28th. Piper Jaffray Companies set a $77.00 price objective on shares of Clovis Oncology and gave the company a “buy” rating in a research report on Tuesday, March 14th. Morgan Stanley started coverage on shares of Clovis Oncology in a research report on Friday, January 13th. They set an “overweight” rating and a $68.00 price objective on the stock. Finally, Goldman Sachs Group Inc boosted their price objective on shares of Clovis Oncology from $44.00 to $75.00 and gave the company a “neutral” rating in a research report on Wednesday, March 15th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $62.33.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $66.99, for a total value of $200,970.00. Following the transaction, the insider now owns 209,583 shares in the company, valued at approximately $14,039,965.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 17.40% of the company’s stock.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

5 Day Chart for NASDAQ:CLVS

Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc (NASDAQ:CLVS).

Receive News & Ratings for Clovis Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.